Zadie Davis

10.3k total citations · 1 hit paper
47 papers, 5.3k citations indexed

About

Zadie Davis is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Zadie Davis has authored 47 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Genetics, 31 papers in Pathology and Forensic Medicine and 19 papers in Immunology. Recurrent topics in Zadie Davis's work include Chronic Lymphocytic Leukemia Research (40 papers), Lymphoma Diagnosis and Treatment (31 papers) and Immunodeficiency and Autoimmune Disorders (17 papers). Zadie Davis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (40 papers), Lymphoma Diagnosis and Treatment (31 papers) and Immunodeficiency and Autoimmune Disorders (17 papers). Zadie Davis collaborates with scholars based in United Kingdom, Greece and Italy. Zadie Davis's co-authors include David Oscier, Terry J. Hamblin, Freda K. Stevenson, Anne Gardiner, Jenny Orchard, Peter Thomas, Rachel Ibbotson, Estella Matutes, Martin Corcoran and Daniel Catovsky and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Zadie Davis

47 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia

1999 2.0k citations Terry J. Hamblin, Zadie Davis et al. Blood profile →

Peers

Countries citing papers authored by Zadie Davis

Since Specialization

Citations

This map shows the geographic impact of Zadie Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zadie Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zadie Davis more than expected).

Fields of papers citing papers by Zadie Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zadie Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zadie Davis. The network helps show where Zadie Davis may publish in the future.

Co-authorship network of co-authors of Zadie Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Zadie Davis. A scholar is included among the top collaborators of Zadie Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zadie Davis. Zadie Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL 2022 ·Leukemia ·Andreas Agathangelidis, Anastasia Chatzidimitriou, Thomas Chatzikonstantinou, Cristina Tresoldi, Zadie Davis, Véronique Giudicelli, Sofia Kossida, Chrysoula Belessi, Richard Rosenquist, Paolo Ghia, Anton W. Langerak, Frédéric Davi, Κώστας Σταματόπουλος	41
2	Evaluation of serum markers in the LRF CLL4 trial: β₂-microglobulin but not serum free light chains, is an independent marker of overall survival 2016 ·Leukemia & lymphoma ·Guy Pratt, Peter Thomas, (unknown), D. Alexander, Zadie Davis, David H. Hussey, Helen Parry, Stephen Harding, Daniel Catovsky, Joe Begley, David Oscier	4
3	Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease 2016 ·Leukemia ·Matthew Rose‐Zerilli, Jane Whitney Gibson, Jun Wang, William Tapper, Zadie Davis, Helen Parker, Marta Larráyoz, Helen O. McCarthy, Renata Walewska, Jade Forster, Amy S. Gardiner, Andrew J. Steele, Claude Chelala, Sarah Ennis, Andrew Collins, Christopher C. Oakes, David Oscier, Jonathan C. Strefford	22
4	Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation 2015 ·Haematologica ·(unknown), Andreas Agathangelidis, Daniele Reverberi, Stavroula Ntoufa, Lydia Scarfò, Pamela Ranghetti, Giovanna Cutrona, Alessandra Tedeschi, Aliki Xochelli, Federico Caligaris‐Cappio, Maurilio Ponzoni, Chrysoula Belessi, Zadie Davis, Miguel Á. Piris, David Oscier, Paolo Ghia, Κώστας Σταματόπουλος, Marta Muzio	22
5	Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia 2013 ·Leukemia & lymphoma ·Pauline Huang, Giles Best, Juhura G. Almazi, Larissa Belov, Zadie Davis, Aneela Majid, Martin J.S. Dyer, Dana Pascovici, Stephen P. Mulligan, Richard I. Christopherson	25
6	Whole Exome Sequencing Identifies Novel Recurrently Mutated Genes in Patients with Splenic Marginal Zone Lymphoma 2013 ·PLoS ONE ·Marina Parry, Matthew Rose‐Zerilli, Jane Whitney Gibson, Sarah Ennis, Renata Walewska, Jade Forster, Helen Parker, Zadie Davis, Anne Gardiner, Andrew Collins, David Oscier, Jonathan C. Strefford	51
7	Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial 2012 ·Journal of Clinical Oncology ·Anna Skowrońska, Anton Parker, (unknown), Ceri Oldreive, Zadie Davis, Sue Richards, Martin J.S. Dyer, Estella Matutes, David González, A. Malcolm R. Taylor, Paul Moss, Peter Thomas, David Oscier, Tatjana Stanković	77
8	Defining the prognosis of early stage chronic lymphocytic leukaemia patients 2011 ·British Journal of Haematology ·Chris Pepper, Aneela Majid, Thet Thet Lin, Saman Hewamana, Guy Pratt, Renata Walewska, Stefan Gesk, Reiner Siebert, Simon D. Wagner, Ben Kennedy, Fiona Miall, Zadie Davis, Ian Tracy, Anne Gardiner, Paul Brennan, Robert K. Hills, Martin J.S. Dyer, David Oscier, Chris Fegan	33
9	Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation 2010 ·Haematologica ·David Oscier, Rachel Wade, Zadie Davis, Alison Morilla, Giles Best, Stephen J. Richards, Monica Else, Estella Matutes, (unknown)	81
10	DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1 2009 ·Experimental Cell Research ·Mikael Lerner, Masako Harada, Jakob Lovén, (unknown), Zadie Davis, David Oscier, Marie Arsenian‐Henriksson, Olle Sangfelt, Dan Grandér, Martin Corcoran	132
11	Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial 2007 ·The Lancet ·Daniel Catovsky, (unknown), Estella Matutes, (unknown), Martin J.S. Dyer, R. F. Bezares, A R Pettitt, (unknown), (unknown), (unknown), William Hamilton, (unknown), (unknown), AG Bosanquet, Zadie Davis, (unknown), Monica Else, Rachel Wade, Peter Hillmen	482
12	Cytogenetic Aberrations and ImmunoglobulinV_HGene Mutations in Clinically Benign CD5– Monoclonal B-Cell Lymphocytosis 2007 ·American Journal of Clinical Pathology ·Dominick Amato, David Oscier, Zadie Davis, Sarah Mould, (unknown), Elena Kolomietz, Chen Wang	23
13	IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL) 2006 ·Leukemia ·Ilaria Del Giudice, Zadie Davis, Estella Matutes, Nnenna Osuji, Nilima Parry‐Jones, Alison Morilla, V Brito-Babapulle, David Oscier, Daniel Catovsky	23
14	Polyreactive Monoclonal Antibodies Synthesized by Some B-CLL Cells Recognize Specific Antigens on Viable and Apoptotic T Cells. 2006 ·Blood ·Rosa Catera, Katerina Hatzi, Charles C. Chu, Maxime Hervé, Eric Meffre, Manlio Ferrarini, David Oscier, Zadie Davis, Steven L. Allen, R. Kanti, Nicholas Chiorazzi	9
15	ZAP-70 expression and prognosis in chronic lymphocytic leukaemia 2004 ·The Lancet ·Jenny Orchard, Rachel Ibbotson, Zadie Davis, Adrian Wiestner, Andreas Rosenwald, Peter Thomas, Terry J. Hamblin, Louis M. Staudt, David Oscier	407
16	The Natural History of Mutated, Stage AO Chronic Lymphocytic Leukemia. 2004 ·Blood ·David Oscier, Anne Gardiner, Sarah Mould, Sharron Glide, Zadie Davis, Martin Corcoran, Adrian Wiestner, Louis M. Staudt, Peter Thomas, Jenny Orchard	1
17	Splenic marginal zone atrophy and progressive CD8+ T‐cell lymphocytosis in HIV infection: a study of adult post‐mortem spleens from Côte d'Ivoire 2003 ·Histopathology ·Bridget S. Wilkins, Zadie Davis, (unknown), Georges Delsol, David B. Jones	18
18	Immunogenetic analysis of the immune response to pneumococcal polysaccharide 2000 ·European Journal of Immunology ·Helen Baxendale, Zadie Davis, Harry N White, Myfanwy B. Spellerberg, Freda K. Stevenson, David Goldblatt	57
19	Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocyte leukemia 1999 ·ePrints Soton (University of Southampton) ·T.J. Hamblin, Zadie Davis, Amy S. Gardiner, David Oscier, Freda K. Stevenson	12
20	Immunogenetic analysis of a panel of monoclonal IgG and IgM anti-PDC-E2/X antibodies derived from patients with primary biliary cirrhosis 1998 ·Journal of Hepatology ·Richard Thomson, Zadie Davis, Jeremy M. Palmer, Michael J.P. Arthur, Stephen J. Yeaman, Caroline Chapman, Myfanwy B. Spellerberg, Freda K. Stevenson	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact